Viridian Therapeutics, Inc. (VRDN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Viridian Therapeutics, Inc. (VRDN) Healthcare & Pipeline Overview

Viridian Therapeutics, Inc. is a biotechnology firm specializing in novel treatments for thyroid eye disease (TED), leveraging its pipeline of IGF-1R-targeting antibodies. With VRDN-001 in Phase 1/2 trials, the company aims to address unmet needs in the TED market, positioning itself among key players in the biotechnology sector.

What Is the Investment Thesis for VRDN?

Viridian Therapeutics presents a focused investment opportunity within the biotechnology sector, driven by its pipeline of IGF-1R-targeting antibodies for thyroid eye disease (TED). The company's lead candidate, VRDN-001, is currently in Phase 1/2 clinical trials, with potential for positive data readouts that could significantly increase its market capitalization. Viridian's gross margin stands at an impressive 99.4%. Key catalysts include the advancement of VRDN-002 and VRDN-003 through clinical development. However, the company's negative profit margin of -508.5% reflects substantial ongoing R&D expenses. The company's beta of 1.17 suggests a slightly higher volatility compared to the market. Successful clinical trial outcomes and potential partnerships could drive significant value, while clinical setbacks or regulatory hurdles represent key risks. The company's market cap is $1.26B as of 2026-05-10.

Based on FMP financials and quantitative analysis

VRDN Key Highlights

Market Cap of $2.78B reflects investor confidence in Viridian's pipeline and potential in the TED treatment market.

• Gross Margin of 99.4% indicates strong potential profitability upon commercialization of its therapeutic candidates.
• Profit Margin of -508.5% highlights the significant R&D investment phase typical of biotechnology companies.
• VRDN-001 is in Phase 1/2 clinical trials for TED, representing a key value driver and potential near-term catalyst.
• Beta of 1.17 suggests a slightly higher volatility compared to the market.

Who Are VRDN's Competitors?

VRDN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VRDN's Key Strengths?

Novel IGF-1R-targeting antibody technology.

• Pipeline of therapeutic candidates focused on TED.
• Experienced management team.
• Strong gross margin potential.

What Are VRDN's Weaknesses?

High R&D expenses leading to negative profit margins.

• Reliance on clinical trial success.
• Limited commercialized products.
• Competition from established pharmaceutical companies.

What Could Drive VRDN Stock Higher?

VRDN-001 Phase 1/2 clinical trial data readouts for thyroid eye disease (TED).

• Advancement of VRDN-002 into later-stage clinical trials.
• Potential partnerships with larger pharmaceutical companies for co-development and commercialization.

What Are the Key Risks for VRDN?

Negative return on equity (-61.3%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for VRDN-001, VRDN-002, or VRDN-003.
• Regulatory delays or rejection of marketing applications.
• Competition from existing and emerging TED treatments.
• Patent disputes or challenges to intellectual property.

What Are the Growth Opportunities for VRDN?

• Expansion of VRDN-001 Clinical Trials: Viridian has the opportunity to expand the clinical trials for VRDN-001 into larger patient populations and different geographies. Successful Phase 2 and Phase 3 trials could lead to accelerated regulatory approval and market entry. The global market for TED treatments is projected to reach $2.5 billion by 2028, offering a substantial revenue opportunity for Viridian. Timeline: Ongoing with potential results within the next 2-3 years.
• Advancement of VRDN-002 and VRDN-003: Progressing VRDN-002 and VRDN-003 through clinical trials represents a significant growth opportunity. Positive preclinical and Phase 1 data could attract partnerships and further investment. These assets diversify Viridian's pipeline and reduce reliance on a single therapeutic candidate. The market for novel antibody therapies is expanding, driven by advancements in biotechnology. Timeline: Ongoing with potential milestones in the next 3-5 years.
• Strategic Partnerships and Collaborations: Viridian can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. Collaborations can provide access to additional funding, expertise, and market reach. The biotechnology industry is characterized by frequent partnerships, offering numerous opportunities for Viridian. Timeline: Ongoing.
• Expansion into Related Therapeutic Areas: Viridian has the potential to leverage its expertise in IGF-1R targeting to develop treatments for other autoimmune and inflammatory diseases. This could broaden the company's pipeline and address unmet needs in additional therapeutic areas. The market for autoimmune disease treatments is substantial and growing. Timeline: Potential expansion within the next 5-7 years.
• Geographic Expansion: Viridian can expand its market reach beyond the United States by seeking regulatory approval and commercializing its products in Europe and Asia. The global market for TED treatments is significant, and geographic expansion could drive substantial revenue growth. Timeline: Potential expansion within the next 3-5 years following initial US approval.

What Are VRDN's Competitive Advantages?

• Proprietary IGF-1R-targeting antibody technology.
• Strong intellectual property portfolio with patents protecting its therapeutic candidates.
• Clinical trial data demonstrating the potential efficacy and safety of its treatments.
• Experienced management team with expertise in drug development and commercialization.

What Does VRDN Do?

Founded in 2006 and headquartered in Waltham, Massachusetts, Viridian Therapeutics, Inc. is a biotechnology company dedicated to developing innovative therapies for patients suffering from serious diseases. Originally known as Miragen Therapeutics, Inc., the company rebranded in January 2021 to reflect its evolving focus. Viridian's primary therapeutic focus is on thyroid eye disease (TED), a debilitating autoimmune disorder. The company's pipeline features a suite of novel antibody candidates designed to target the insulin-like growth factor 1 receptor (IGF-1R). These include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently in Phase 1/2 clinical trials; VRDN-002, another IGF-1R antibody in Phase 1 clinical trials; and VRDN-003, a therapeutic antibody also targeting IGF-1R for TED treatment. Viridian's research and development efforts are geared towards providing improved treatment options for TED patients, addressing the limitations of existing therapies. The company operates with 143 employees, focusing on advancing its clinical programs and expanding its intellectual property portfolio within the competitive biotechnology landscape.

What Products and Services Does VRDN Offer?

• Develops treatments for patients suffering from serious diseases.
• Focuses on thyroid eye disease (TED) therapeutics.
• Develops humanized monoclonal anti-IGF-1R antibodies.
• Conducts Phase 1/2 clinical trials for VRDN-001.
• Develops VRDN-002, an IGF-1R antibody in Phase 1 clinical trial.
• Develops VRDN-003, a therapeutic antibody targeting IGF-1R for TED treatment.

How Does VRDN Make Money?

• Develops and patents novel therapeutic antibodies.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from the FDA and other agencies.
• Potentially commercializes products directly or through partnerships.

What Industry Does VRDN Operate In?

Viridian Therapeutics operates within the biotechnology industry, which is characterized by high growth potential and significant R&D investment. The market for thyroid eye disease (TED) treatments is growing, driven by increasing awareness and the limitations of existing therapies. Competition includes companies like IBRX: ImmunityBio, Inc. and COGT: Cogent Biosciences, Inc., which are developing treatments for various immunological and oncological disorders. The biotechnology sector is subject to stringent regulatory requirements and clinical trial risks, but successful drug development can lead to substantial market rewards. Viridian's focus on IGF-1R targeting positions it within a competitive but promising niche.

Who Are VRDN's Key Customers?

• Patients suffering from thyroid eye disease (TED).
• Healthcare providers who treat TED patients.
• Pharmaceutical companies interested in licensing or acquiring novel therapeutics.

Company Profile

Viridian Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Stephen F. Mahoney. VRDN has traded publicly since 2014.

Viridian Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.92 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for Viridian Therapeutics, Inc. stands at -61.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 16.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.9%, the inverse of the P/E and a quick read on earnings relative to price.

VRDN Valuation & Market Position

With a $2.78B market cap, Viridian Therapeutics, Inc. sits in the mid-cap segment of the market. Relative to its peer group, VRDN's quantitative score of 22/100 is below the peer average of 66/100.

Wall Street analysts project Viridian Therapeutics, Inc. revenue of about $21.6M for fiscal 2026, with EPS near $-3.85. The estimate reflects 10 contributing analysts.

VRDN Financials

VRDN Latest News

VRDN Analyst Consensus

VRDN MoonshotScore

VRDN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources